Why the study?
Does the ionic contrast agent ioxaglate reduce acute thrombotic events compared to the nonionic agent iohexol in patients undergoing PTCA?
Does the ionic contrast agent ioxaglate reduce acute thrombotic events compared to the nonionic agent iohexol in patients undergoing PTCA?
The use of the ionic contrast agent ioxaglate during PTCA significantly reduces acute in-laboratory thrombotic events compared to the nonionic agent iohexol.
Answers are grounded in this paper and cite their sources.
Supports ioxaglate over iohexol in PTCA to reduce thrombotic events; extends RCT evidence favoring ionic contrast.
An increasing body of evidence suggests that the potential for thrombotic complications is greater with nonionic than with ionic contrast agents. This is a particularly important consideration in the highly thrombogenic setting of percutaneous transluminal coronary angioplasty (PTCA). To explore this issue further, 500 consecutive patients undergoing PTCA were prospectively randomized to receive the low osmolality ionic ioxaglate or the nonionic agent iohexol. The number of acute thrombotic in-laboratory events was significantly less in the ioxaglate than in the iohexol group (8 versus 18; P < 0.05), but there was no significant difference between the 2 groups as regards the number of out-of-laboratory acute rethrombotic events. With multivariate analysis, use of the nonionic agent rather than the ionic agent emerged as an independent predictor of acute in-laboratory rethrombosis. These data suggest that, in the performance of PTCA, an ionic, rather than a nonionic, should be the preferred contrast agent.
No takes yet. Share an insight, caveat, or question.
Piessens et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: